下載本文檔
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEMKT-077Cat. No.: HY-15096CAS No.: 147366-41-4Synonyms: FJ-776分式: CHClNOS分量: 432作靶點(diǎn): HSP作通路: Cell Cycle/DNA Damage; Metabolic Enzyme/Protease儲(chǔ)存式: Powder -20C 3 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 41.67 mg/mL
2、 (96.46 mM; Need ultrasonic)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 2.3148 mL 11.5741 mL 23.1481 mL5 mM 0.4630 mL 2.3148 mL 4.6296 mL10 mM 0.2315 mL 1.1574 mL 2.3148 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲(chǔ)備液,并請(qǐng)注意儲(chǔ)備液的保存式和期限。體內(nèi)實(shí)驗(yàn) 請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥式選擇適當(dāng)?shù)娜芙獍?,配制前?qǐng)先配制澄清的儲(chǔ)備液,再依次添加助溶劑(為保證實(shí)驗(yàn)結(jié)果的可靠性,體內(nèi)實(shí)驗(yàn)的作液,建議您現(xiàn)現(xiàn)配,
3、當(dāng)天使;澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件,適當(dāng)保存;以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占):1. 請(qǐng)依序添加每種溶劑: 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.08 mg/mL (4.81 mM); Clear solution2. 請(qǐng)依序添加每種溶劑: 10% DMSO 90% corn oilSolubility: 2.08 mg/mL (4.81 mM); Clear solution1/3 Master of Small Molecules 您邊的抑制劑師www.MedChemEBIOLOGICAL AC
4、TIVITY物活性 MKT-077種花菁染料,也 種熱休克蛋 70 (Hsp70) 抑制劑,且具有顯著的抗腫瘤活性。IC50 & Target HSP70體外研究 MKT-077 is a rhodacyanine dye and also a heat shock protein 70 (Hsp70) inhibitor which exhibits significantantitumor activity. MKT-077 treatment (0.1 to 10 M dose ranges) for 48 hours can effectively decrease TTcell vi
5、ability. MKT-077 treatment results in accumulation of cells in the G0/G1 phase in a dose-dependentmanner, and also increases sub-G0/G1 phase population in TT cell culture in a dose-dependent manner.MKT-077 also downregulates cellular levels of the proliferation marker, Ki67, and the S-phase transcri
6、ptionfactor, E2F-1, in TT and MZ-CRC-1 cells. Moreover, flow cytometry using different doses of MKT-077reveales that TT cells can uptake and retain MKT-077 at significantly higher levels than MZ-CRC-1 cells 1.MKT-077 has EC50 values of 1.40.2 and 2.20.2 M against MDA-MB-231 and MCF7 breast cancer ce
7、lls,respectivelyl 2.體內(nèi)研究 Systemic administration of MKT-077 significantly delays the growth of TT xenografts in mice throughout thetreatment. At the end of MKT-077 treatment, it is found that tumor weights are about two-times less in MKT-077-treated group than in control group. MKT-077 treatment als
8、o results in weight loss and general toxicity inanimals 1. Results show that the succinate-induced, ADP-stimulated respiratory rate in mitochondriaisolated from the liver of rats treated with a bolus i.v. injection of 15 mg MKT-077 1kg body weight each dayfor 5 days is significantly lower than that
9、of untreated controls 3.PROTOCOLCell Assay 1 Cells are incubated with 1 M MKT-077 and 100 nM Mitotracker Green FM in culture medium for 30 minutesat 37C in the dark, washed with PBS, switched into phenol-red free medium before visualizing fluorescenceunder a microscope. Pictures are acquired and pro
10、cessed with software. For flow cytometric measurement,MKT-077-treated cells are resuspended in 0.1% bovine serum albumin/PBS and analyzed by flow cytometry.Data from 20,000 cells are analyzed using FCS Express software 1.MCE has not independently confirmed the accuracy of these methods. They are for
11、 reference only.Animal The 1107 TT cells in 200 L Hanks balanced salt solution are inoculated subcutaneously into the rearAdministration 1 flanks of 6-week-old female athymic nude (nu/nu) mice. Once palpable, tumors are measured using calipersat intervals indicated in the text. When tumor volume rea
12、ches 100 mm3, mice are sorted into groups of 8 toachieve equal distribution of tumor size in all treatment groups. Group 1 receives only the vehicle (1:9mixture of DMSO/saline) and group 2 receives MKT-077 (10 mg/kg body weight/dose). A 200 L of ethersolution is administered by intraperitoneal injec
13、tion every 2 days (total 10 doses). At the end of theexperiments, animals are euthanized by CO2 asphyxiation 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemE1. Starenki D, et al. Selective Mit
14、ochondrial Uptake of MKT-077 Can Suppress Medullary Thyroid Carcinoma Cell Survival In Vitro and InVivo. Endocrinol Metab (Seoul). 2015 Dec;30(4):593-603.2. Li X, et al. Analogs of the Allosteric Heat Shock Protein 70 (Hsp70) Inhibitor, MKT-077, as Anti-Cancer Agents. ACS Med Chem Lett.2013 Nov 14;4(11).3. Weisberg EL, et al. In vivo administration of MKT-077 causes partial yet reversible impairment of mitochondrial function. Cancer Res.1996 Fe
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 2025年代理商代理傭金費(fèi)協(xié)議
- 2025年大型露天演出場(chǎng)地租用協(xié)議
- 2025年生存保險(xiǎn)受益人變更申請(qǐng)
- 《用友業(yè)務(wù)流程》課件
- 二零二五版增值稅發(fā)票委托第三方服務(wù)框架協(xié)議3篇
- 事業(yè)單位2024年度勞動(dòng)合同定制版
- 二零二五年度知識(shí)產(chǎn)權(quán)侵權(quán)賠償合同補(bǔ)充協(xié)議3篇
- 二零二五年節(jié)能減排服務(wù)合同2篇
- 2021-2026年中國血?dú)夥治鰞x市場(chǎng)供需現(xiàn)狀及投資戰(zhàn)略研究報(bào)告
- 2025年針刺毯項(xiàng)目可行性研究報(bào)告
- 2025新譯林版英語七年級(jí)下單詞表
- 新疆2024年中考數(shù)學(xué)試卷(含答案)
- 2024-2030年中國連續(xù)性腎臟替代治療(CRRT)行業(yè)市場(chǎng)發(fā)展趨勢(shì)與前景展望戰(zhàn)略分析報(bào)告
- 跨學(xué)科主題學(xué)習(xí):實(shí)施策略、設(shè)計(jì)要素與評(píng)價(jià)方式(附案例)
- 場(chǎng)地委托授權(quán)
- 2024年四川省成都市龍泉驛區(qū)中考數(shù)學(xué)二診試卷(含答案)
- 項(xiàng)目工地春節(jié)放假安排及安全措施
- 印染廠安全培訓(xùn)課件
- 紅色主題研學(xué)課程設(shè)計(jì)
- 裝置自動(dòng)控制的先進(jìn)性說明
- 《企業(yè)管理課件:團(tuán)隊(duì)管理知識(shí)點(diǎn)詳解PPT》
評(píng)論
0/150
提交評(píng)論